Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma

被引:29
作者
Yenidunya, Sibel [1 ]
Bayrak, Reyhan [1 ]
Haltas, Hacer [1 ]
机构
[1] Fatih Univ Hosp, Dept Pathol, Ankara, Turkey
关键词
BASAL CYTOKERATIN EXPRESSION; CLINICAL CHARACTERIZATION; PROGESTERONE-RECEPTORS; ADJUVANT THERAPY; EARLY RECURRENCE; CANCER PATIENTS; TUMOR SIZE; GENE; PHENOTYPE; PROGNOSIS;
D O I
10.1186/1746-1596-6-18
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background/Objective: While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. Axillary lymph node metastasis (ALNM) is one of the most important prognostic determinants in breast carcinoma; however, the reasons why tumors vary in their capability to result in axillary metastasis remain unclear. Identifying breast carcinoma patients at risk for ALNM would improve treatment planning. This study aimed to identify the factors associated with ALNM in breast carcinoma, with particular emphasis on basal-like phenotype. Methods: Breast carcinoma patients (n = 210) who underwent breast conserving surgery and axillary lymph node dissection (ALND) (level I and II) or modified radical mastectomy were included in this study. Pathological and immunohistochemical data including individual receptor/gene status was collected for analysis. The basal phenotype status was ascertained using the basal cytokeratin markers CK5, CK14, CK17 and EGFR. Results: ALNM was found in 55% (n = 116) of the patients. On univariate analysis, multicentric disease, large tumor size (> 2 cm), vascular and lymphatic invasion, epithelial hyperplasia, necrosis, in situ carcinoma and perineural invasion were associated with higher risk for ALNM, whereas CK5, CK14, EGFR positivity and basal-like tumor type were associated with lower risk. On multivariate analysis, CK5 positivity (OR 0.003, 95% CI 0.000-0.23, p = 0.009) and lymphatic/vascular invasion (OR 17.94, 95% CI 4.78-67.30, p < 0.001) were found to be independent predictors. Conclusions: Although the value of complete ALND has been questioned in invasive breast cancer patients, treatment decisions for breast carcinoma have been influenced by many parameters, including lymph node status. Since histopathologic characteristics and expression of biological markers varies among the same histologic subtypes of breast carcinoma, specific clinical and histopathologic features of the primary tumor and ALN status like sentinel node might be used to tailor the loco-regional and systemic treatment in different clinical settings.
引用
收藏
页数:9
相关论文
共 67 条
[31]   Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients [J].
Kulic, A. ;
Sirotkovic-Skerlev, M. ;
Jelisavac-Cosic, S. ;
Herceg, D. ;
Kovac, Z. ;
Vrbanec, D. .
MEDICAL ONCOLOGY, 2010, 27 (03) :887-893
[32]  
KWON Y, 2011, ONCOL REP
[33]   Predictors of Axillary Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM Irrespective of the Tumor Size [J].
Lee, Jong Hoon ;
Kim, Sung Hwan ;
Suh, Young Jin ;
Shim, Byoung Yong ;
Kim, Hoon Kyo .
CANCER RESEARCH AND TREATMENT, 2010, 42 (01) :30-36
[34]  
Lester SC, 2009, ARCH PATHOL LAB MED, V133, P1515, DOI 10.1043/1543-2165-133.10.1515
[35]  
Liu ZB, 2009, TUMORI J, V95, P53
[36]  
Maibenco DC, 1999, CANCER, V85, P1530, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1530::AID-CNCR14>3.3.CO
[37]  
2-L
[38]   Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas [J].
Malzahn, K ;
Mitze, M ;
Thoenes, M ;
Moll, R .
VIRCHOWS ARCHIV, 1998, 433 (02) :119-129
[39]   Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial [J].
Mansel, RE ;
Fallowfield, L ;
Kissin, M ;
Goyal, A ;
Newcombe, RG ;
Dixon, JM ;
Yiangou, C ;
Horgan, K ;
Bundred, N ;
Monypenny, I ;
England, D ;
Sibbering, M ;
Abdullah, TJ ;
Barr, L ;
Chetty, U ;
Sinnett, DH ;
Fleissig, A ;
Clarke, D ;
Ell, PJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (09) :599-609
[40]   Global breast cancer mortality statistics [J].
Mettlin, C .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (03) :138-144